Navigation Links
Study of successful drug targets could hasten development of new medications
Date:1/31/2008

Guidance from an innovative computational approach could speed up the process and cut down the cost of new drug development, researchers from the University of Chicago Medical Center and Columbia University suggest in a study to be published in the February 2008 issue of Genome Research, available early online.

The researchers analyzed specific properties of the human genes and proteins that serve as targets for nearly a thousand FDA-approved drugs. They identified a number of characteristics that were common among successful drug targetsand especially common among high-revenue drugs.

"To make a good drug, you need to find a good drug target," said Andrey Rzhetsky, PhD, professor of medicine at the University of Chicago and senior author of the study. "Here we provide guidelines for more efficient target screening. When a drug company must decide which target to pursue among pathologic pathways, this could provide useful estimates of each target's expected success rate."

Gleevec, Prozac, Viagra: these successful drugs all target specific proteins and provoke a desired response. They reward the people who need them, as well as to those who invent, manufacture and market them.

But he development of a new drug is complicated and expensive, "a fusion of art and science," the authors note. It involves finding an accessible drug target and a molecule that binds that target as selectively as possible. Then it must trigger a desirable physiological change.

But "every highly visible success," the authors note, "rests on an iceberg of invisible failures." Since the estimated cost of developing a new drug ranges from $800 million to $1.2 billion, "information that helps only a little bit," Rzhetsky said, "can still be quite valuable."

What characteristics, they asked, distinguished the targets that eventually became the focus of such successful drugs" How are these genes or proteins different from the tens of thousands of less desirable targets"

To find out, the researchers looked at the relationships between 919 successful drugs, their human gene or protein targets, and the functional properties of those targets.

They found that most successful drugs are very precise; 62% of them have only one specific target.

But that's just a start. "A target molecule with an appropriate, 'drugable' structure is a necessary but not sufficient condition for success," write the authors. But the selection of a prospective drug target is "a complicated balance of many considerations,"

Additional properties that distinguish most good targets include:

  • Connectivity--how many other proteins does the target protein interact with directly" Effective drugs targets--according to Rzhetsky and colleague Lixia Yao, from Columbia University--interact with about nine other genes or proteins, which is above average but not extremely high. This is enough connections to have a significant impact but not so many as to multiply the risks of serious side effects. The very-high-revenue drugs, the authors note, tend to target genes and proteins with slightly lower connectivity.
  • Betweenness--how often does this protein serve as the shortest path between two networks of proteins" Successful drugs, they found, tend to bridge two of more clusters of interacting molecules.
  • Consistency--how much does the gene for this protein vary from person to person" Limited individual variation is better, so the drug works the same way in most people.
  • Tissue specificity--where is the gene for the drug target expressed" In just one tissue, say brain, or skin, or all over the body" Ideally, the researchers found that the best targets were genes or proteins primarily expressed in one specific tissue, so the drug treats the disease at its core, without interfering with other, healthy tissues or organs, and thus causes fewer side-effects. Six tissue types, they found, were significantly "undertargeted" by pharmaceutical research: male reproductive tissues, embryonic structures, skin, cartilage, bone and lymph.
  • Overlap--Finally, successful drug targets significantly overlap with disease genes--those in which a mutation can cause a specific disease, such as cystic fibrosis--and with essential genes, that are required for normal development.

"We found that genes associated with successful FDA-approved drugs have several properties at the network, sequence, and tissue-expression levels that significantly distinguish them from other human genes," the authors conclude. "Although the drug target-selection guidelines that we suggest cannot replace expensive experiments, they can help at the earliest stage of a drug-development project."


'/>"/>

Contact: John Easton
John.Easton@uchospitals.edu
772-702-6241
University of Chicago Medical Center
Source:Eurekalert

Related biology news :

1. Conservation strategies must shift with global environmental change, says CU-Boulder study
2. Virginia Tech plant scientist leads study on genomics of parasitic plants
3. Smithsonian study: Sediment prediction tools off the mark
4. Prison study to investigate link between diet and behavior
5. Queens study connects obesity with nervous system
6. LSU, Yale team study agricultural impact on Mississippi River
7. Diet and lifestyle critical to recovery, says study
8. Scientists study the link between childrens nutrition and adult diseases
9. New Argonne study may shed light on protein-drug interactions
10. Sea otter study reveals striking variability in diets and feeding strategies
11. Study: weight-loss tips differ in African-American, mainstream magazines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... 2017 Vigilant Solutions , a vehicle ... agencies, announced today the appointment of retired FBI special ... safety business development. Mr. Sheridan brings more ... a focus on the aviation transportation sector, to his ... Mr. Sheridan served as the Aviation Liaison Agent Coordinator ...
(Date:3/9/2017)... March 9, 2017 4Dx has publicly released ... Imaging Workshop at the University of Pennsylvania. Founder and ... deliver the latest data to world leaders in lung ... together leaders at the forefront of the industry to ... "The quality of the imaging is ...
(Date:3/2/2017)... 2, 2017 Summary This report provides ... its partnering interests and activities since 2010. ... Read the full report: ... since 2010 report provides an in-depth insight into the partnering ... On demand company reports are prepared upon purchase ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... Calif. , March 24, 2017   Sienna ... and aesthetics company, today announced that Richard Peterson ... effective March 24.   Peterson, who brings more ... John Smither , who is retiring at the ... in an advisory capacity. Peterson joins Sienna from Novan, ...
(Date:3/23/2017)... Research and Markets has announced the addition of ... offering. ... The Global Market for Bioproducts Should Reach $714.6 Billion ... of 8.9%, This research report quantifies the ... product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), biocomposite ...
(Date:3/23/2017)...  BioPharmX Corporation (NYSE MKT: BPMX), a specialty ... today reported financial results for the quarter and ... an update on the company,s clinical development efforts ... are pleased to report that last year was ... Anja Krammer. "We achieved key clinical milestones and ...
(Date:3/23/2017)... March 23, 2017 According to a report ... derivatives market is fragmented due to the presence of a large pool ... Thermo Fisher , and Sigma-Aldrich, compete with each other in ... collectively, held more than 76% of this market in 2016.  ... As of now, a ...
Breaking Biology Technology: